Open an account

Tvardi Therapeutics

TVRD · NASDAQ

$0.992+$0.022 (+2.27%)TodayMarket closed ·
Prev close $0.97

About TVRD

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company is headquartered in Sugar Land, Texas and currently employs 12 full-time employees. The company went IPO on 2014-01-31. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Employees
12
Headquarters
Sugar Land, Texas
Listed
Jan 31, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
tvarditherapeutics.com

TVRD key statistics

Market cap
13.23M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
231.79K
Volume
195.19K
Open price
$1.03
High today
$1.08
Low today
$0.97
52 Week high
$6.43
52 Week low
$0.93

Tvardi Therapeutics (TVRD) at a glance

As of Oct 20, 2026, Tvardi Therapeutics (TVRD) shares are priced at $0.992, giving the company a market cap of 13.23M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.97 and $1.08. The current price is 2.3% above the day's low and 7.8% below its high.

Volume so far is 195.19K shares, in line with the average of 231.79K shares a day.

Over the past year Tvardi Therapeutics has ranged from $0.93 to $6.43, and now sits 1% of the way up that range.

Tvardi Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.69 per share against an estimate of -$0.7181.

The average analyst price target is $9.44, 851.1% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

71%of 7 analyst ratings say Buy
  • Buy71.4%
  • Hold14.3%
  • Sell14.3%
Price target · 10 analystsAvg $9.44
Low
$3.03
Now
$0.992
High
$14.70

TVRD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 14.6% on average.

  1. Q2 FY24: reported -$13.32 per share against an estimate of -$10.06
  2. Q3 FY24: reported -$8.28 per share against an estimate of -$9.06
  3. Q1 FY25: reported -$3.22 per share against an estimate of -$0.357
  4. Q2 FY25: reported -$1.00 per share against an estimate of -$0.5833
  5. Q3 FY25: reported -$0.59 per share against an estimate of -$1.02
  6. Q4 FY25: reported -$0.78 per share against an estimate of -$0.6592
  7. Q1 FY26: reported -$0.73 per share against an estimate of -$0.7592
  8. Q2 FY26: reported -$0.69 per share against an estimate of -$0.7181

TVRD news

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Vandana Singh

    Why Is Tvardi Therapeutics Stock Falling Thursday?

  • Vandana Singh

    Why Is Tvardi Therapeutics Stock Gaining Tuesday?

  • Press releasePRNewswire

    INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Press releaseBusiness Wire

    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Press releasePRNewswire

    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Press releasePRNewswire

    TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Press releasePRNewswire

    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

Similar companies

Companies in the same industry as Tvardi Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.